Use of erythropoietin

Details Use of erythropoietin Use of erythropoietin

2003-07-25

2010-06-29

Tsang, Cecilia (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

Reexamination Certificate

active

07745387

ABSTRACT:
The present invention relates to the use of erythropoietin for stimulating the physiological mobilization, proliferation and differentiation of endothelial progenitor cells, for stimulating vasculogenesis, for the therapy of diseases associated with a dysfunction of endothelial progenitor cells and for producing pharmaceutical compositions for the treatment of such diseases, and pharmaceutical compositions which comprise erythropoietin and other suitable active ingredients for stimulating endothelial progenitor cells.

REFERENCES:
patent: 4992419 (1991-02-01), Woog et al.
patent: 5198417 (1993-03-01), Donahue et al.
patent: 5837675 (1998-11-01), Brox
patent: 5980887 (1999-11-01), Isner et al.
patent: 6274158 (2001-08-01), Zaharia
patent: 6284260 (2001-09-01), Czeizler
patent: 6748154 (2004-06-01), O'Leary et al.
patent: 6784154 (2004-08-01), Westenfelder
patent: 7232797 (2007-06-01), Farrell et al.
patent: 2002/0045255 (2002-04-01), Powell
patent: 2002/0065214 (2002-05-01), Iaina et al.
patent: 2002/0137145 (2002-09-01), Powell
patent: 2003/0130197 (2003-07-01), Smith-Swintosky et al.
patent: 198 57 609 (2000-06-01), None
patent: 0 456 153 (1991-11-01), None
patent: 0613683 (1994-02-01), None
patent: 0 613 683 (1994-09-01), None
patent: WO 87/03204 (1987-06-01), None
patent: WO 89/07944 (1989-09-01), None
patent: WO 89/07944 (1989-09-01), None
patent: WO 92/15323 (1992-09-01), None
patent: WO 96/14081 (1996-05-01), None
patent: WO 98/10650 (1998-03-01), None
patent: WO 98/10650 (1998-03-01), None
patent: WO 00/35475 (2000-06-01), None
patent: WO 00/61164 (2000-10-01), None
patent: WO 00/61164 (2000-10-01), None
patent: WO 01/82952 (2001-11-01), None
patent: WO 01/82953 (2001-11-01), None
patent: WO 02/14356 (2002-02-01), None
patent: WO 02/053580 (2002-07-01), None
patent: WO 02/085940 (2002-10-01), None
patent: WO 03/037273 (2003-05-01), None
patent: WO 03/037273 (2003-05-01), None
patent: WO 03/057242 (2003-07-01), None
patent: WO 2004/012759 (2004-02-01), None
Fatouros MS et al “Influence of growth factors erythropoietin and granulocyte macrophage colony stimulating factor on mechanical strength and healing of colonic anastomoses in rats,” Eur J Surg. Oct. 1999;165(10):986-92.
Krussel JS, et al, “Vascular endothelial growth factor (VEGF) mRNA splice variants are differentially expressed in human blastocysts,” Mol Hum Reprod. Jan. 2001;7(1):57-63.
Janquet, Kai, et al., Brief Communication, Erythropoietin and VEGF Exhibit Equal giogenic Potential, Jun. 25, 2002, pp. 326-333 (from Applicant's IDS).
Llevadot, Joan, et al., HMG-CoA Reductase Inhibitor Mobilizes Bone Marrow-Derived Engothelial Progenitor Cells, Apr. 26, 2001, pp. 399-405.
Jaquet, Kai, et al., Brief Communication Erythropoietin and VEGF Exhibit Equal Angiogenic Potential, Jun. 25, 2002, pp. 326-333.
Asahara, Takayuki, et al., VEGF Contributes to Postnatal Neovascularization By Mobilizing. Bone Marrow-Derived Endothelial Progenitor Cells, The EMBO Journal, vol. 18, No. 14; pp. 3964-3972, 1999.
Ribatti, D. “A potential role of erythropoietin in angiogenesis associated with myelodysplastic syndromes”Leukemia, 16(9):1890 (2002).
Catalano C., et al., “Erythropoietin is Beneficial in Mitomycin-Induced Hemolytic-Uremic Syndrome”,Nephron, 91:324-326 (2002).
Quaschning T., et al., “Erythropoietin-induced excessive erythrocytosis activates the tissue endothelin system in mice.”The FASEB Journal, 17(2):259-261 (2002).
Ribatti, D., et al., “Erythropoietin as an angionic factor in gastric carcinoma”,Histopathology, 42(3):246-250 (2003).
Chong, Z. Z., et al., “Erythropoietin Is a Novel Vascular Protectant Through Activation of Akt1 and Mitochondrial Modulation of Cysteine Proteases”Circulation, 106(23):2973-2979 (2002).
Sanz, C., et al., “Nuclear Factor k B is activated in myelodysplastic bone marrow cells”Haematologica.
Z. Tongfeng, “Protective effect of L-arginine on acute renal failure”,J. Nephrol Daily Translplant, 8(6):550-551 (1999).
Z. Yun, “Protective Effect of Simvastatin for Renal Function in Diabetic Nephropathies”,Chin. J. New Drugs Clin. Rem., 19(2):105-107 (2000).
International Search Report dated Apr. 20, 2004.
Zhao Zhong Chong, et al., “Angiogenesis and Plasticity: Role of Erythropoietin in Vascular Systems”,Journal of Hematotherapy&Stem Cell Research, 11:863-871 (2002).
Dunst J., et al., Anemia and Elevated Systemic Levels of Vascular Endothelial Growth Factor (VEGF),Strahlenther and Onkologie, 8:436-441 (2002).
Kling, P.J., “Roles of erythropoietin in human milk”,Acta Pædiatr Suppl, 438:31-35 (2002).
Borawski, J., et al., “Effects of Recombinant Erythropoietin Therapy on Circulating Endothelial Markers in Hemodialysis Patients”,Clin Appl Thrombosis/Hemostasis, 8(1):77-84 (2002).
Gunga, H., et al., “Austrian Moderate Altitude Study (AMAS 2000)—fluid shifts, erythropoiesis, and angiogenesis in patients with metabolic syndrome at moderate altitude (≅1700 m)”,Eur J Appl Physiol, 88:497-505 (2003).
Jaquet K., et al., “Erythropoietin and VEGF Exhibit Equal Angiogenic Potential”,Microvascular Research, 64:326-333 (2002).
Yasuda, Y., et al., “Erythropoietin is involved in growth and angiogenesis in malignant tumours of female reproductive organs”,Carcinogenesis, 23(11):1797-1805 (2002).
Suzuki, N., et al., “Erythroid-specific expression of the erythropoietin receptor rescued its null mutant mice from lethality”,Blood, 100(7):2279-2288.
Buemi, M., et al., “Recombinant Human Erythropoietin Influences Revascularization and Healing in a Rat Model of Random Ischaemic Flaps”,Acta Derma Venereol, 82:411-417 (2002).
Kapiteijn, K., et al., “Steroids and Cytokines in Endometrial Angiogenesis”,Anticancer Research, 21:4231-4242 (2001).
Yasuda, Y., et al., “Expression of erythropoietin in human female reproductive organs”,Ital J Anat Embryol., 106(2 Suppl 2):215-222 (2001).
Wagner, P., et al., “Muscle angiogenic growth factor gene responses to exercise in chronic renal failure”,Am J Physiol Regulatory Integrative Physiol, 281:R-539-R-546 (2001).
Noguchi, K. et al., “Effect of 1-week treatment with erythropoietin on the vascular endothelial function in anaesthetized rabbits”,British Journal of Pharmacology, 133:395-405 (2001).
Raksuan K., et al., “Cardiac function, microvascular structure, and capillary hematocrit in hearts of polycythemic rats”,Am J Physiol Heart Circ Physiol, 281:H2425-H2431 (2001).
Sasaki, R., et al., “Pleiotropic Functions and Tissue-Specific Expression of Erythropoietin”,News Physiol. Sci., 16:110-113 (2001).
Eckardt, K., “Anaemia in end-stage renal disease: pathophysiological considerations”Nephrol Dial Transplant, 16(Suppl 7):2-8 (2001).
Wiessner, C., et al., “Increased Cerebral Infarct Volumes in Polyglobulic Mice Overexpressing Erythropoietin”,Journal of Cerebral Blood Flow and Metabolism, 21:857-864 (2001).
Kobayashi, T, et al., “Effects of Recombinant Human Erythropoietin Therapy on Blood Coagulation and Fibrinolysis System”,Ann Thorac Cardiovasc Surg, 7(5):273-277 (2001).
Locatelli, F., et al., “Cardiovascular disease determinants in chronic renal failure: clinical approach and treatment”Nephrol Dial Transplant, 16:459-468 (2001).
Matsuzaki, S., et al., “Erythropoietin concentrations are elevated in the peritoneal fluid of women with endometriosis”,Human Reproduction, 16(5):945-948 (2001).
Prchal, J.T., et al., “Lessons to better understanding of hypoxia sensing. Acquired and congenital mutations resulting in polycythemia”,Adv Exp Med Biol., 502:189-205 (2001).
Vaziri, N. D., “Cardiovascular effects of erythropoietin and anemia correction”,Curr Opin Nephrol Hypertens, 10(5):633-637 (2001).
Pelletier, L., et al., “An In Vitro Model for the Study of

Affiliated with

Also associated with

Rating

Use of erythropoietin does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of erythropoietin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of erythropoietin will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4238314